Novo Nordisk under pressure to diversify its drug portfolio

Novo Nordisk investors demand acquisitions and new drugs.

Published 1j3 sources✓ ConfirmedImportantupdated 14h

≈ 14sSpeed

The fact

The Ozempic maker prepares for a high-stakes shareholders' meeting.

Dependence on diabetes and obesity treatments concerns shareholders.

3 sources — click a link to read an article on the topic:

Explore this topic

Auto-synthesis from 3 media sources · identified on September 20, 2026